Amylin analogs for the treatment of obesity without diabetes: present and future
Authors:
- 30 September 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (10) , 891-899
Abstract
IntroductionObesity is a pandemic, linked with increased morbidity including diabetes mellitus (DM) and certain cancer types. Amylin is a major regulatory hormone for satiation and food intake perception in humans. Amylin analogs (pramlintide and cagrilintide) are emerging as promising anti-obesity agents in non-DM subjects.Areas coveredPramlintide, the first amylin analog, initially used for the treatment of both type 1 and type 2 DM, has demonstrated weight-lowering action. Clinical trials confirmed a weight loss exceeding 3% in the study period without major untoward effects, which was maintained beyond the follow-up period. Recently, cagrilintide, a long-lasting synthetic amylin analog has been introduced. Cagrilintide has achieved adequate weight loss, reaching even more than 10% of the total weight in early clinical trials. However, adverse gastrointestinal effects, particularly nausea, were more frequent compared with pramlintide. Clinical trials have also confirmed the effectiveness of cagrilintide in comparison with glucagon-like peptide 1 receptor agonists.Expert opinionAmylin analogs will certainly enrich the growing therapeutic armamentarium aimed at tackling obesity. The most exciting future research venue could be the development of their combinations with other weight-lowering drugs, especially dual and triple incretin-based co-agonists, thus potentially providing massive weight-loss effects.Keywords
This publication has 44 references indexed in Scilit:
- Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysisBiomedicine & Pharmacotherapy, 2024
- Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?Diabetes Therapy, 2023
- A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage onMetabolism, 2022
- The new dual gastric inhibitory peptide/glucagon‐like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?Diabetes/Metabolism Research and Reviews, 2021
- The epidemiology of obesityMetabolism, 2019
- Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid SignalingBiological Psychiatry, 2017
- Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitusClinical Therapeutics, 2007
- Pramlintide in the treatment of type 1 and type 2 diabetes mellitusClinical Therapeutics, 2005
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetesDiabetologia, 2005
- Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysisMetabolism, 2003